INTRODUCTION
Type 1 diabetes mellitus is a disease in which destruction or damage of pancreatic β-cells results in marked hyperglycemia and ketosis, and is classified as either autoimmune (type 1A) or idiopathic (type 1B) diabetes. The destruction of β-cells in autoimmune type 1 diabetes occurs slowly, with onset of ketosis several years after initiation of β-cell damage. However, unlike the manifestation of autoimmune type 1 diabetes, some patients experience rapid destruction of β-cells, resulting in an abrupt onset of hyperglycemia and ketoacidosis. This condition is known as fulminant type 1 diabetes. In this type of diabetes, the duration of disease starting from a normal β-cell mass and normoglycemia to almost total destruction of β-cells and ketoacidosis is usually only a few days, and rarely exceeds 1 week. Thus, in patients with fulminant type 1 diabetes, symptoms occur within a week, but glycated hemoglobin (HbA1c) levels remain normal or near-normal. 1 Since 2005, several fulminant type 1 diabetes cases have been reported in South Korea; however, there have been no reports of cases in patients previously diagnosed with type 2 diabetes mellitus.
Here, we report a rare case of fulminant type 1 diabetes in a patient with type 2 diabetes.
CASE REPORT
A 51-year-old female presented to the Chungnam National University Hospital emergency room complaining of general weakness and hyperglycemia in January 2015. She had previously been diagnosed with type 2 diabetes at a local medical center in March 2014.
At the time of diagnosis, her fasting plasma glucose was 140 mg/dL and her HbA1c was 7.0%; C-peptide levels were not evaluated. The patient's blood glucose levels were well controlled with glimepiride (0.5-1 mg/day) and her HbA1c level had been 6.5% four months prior to the current visit. Three days before admission, her blood glucose levels had gradually increased to over 400 mg/dL, and her symptoms of polydipsia and general weakness worsened.
The patient was alert on admission, and her blood pressure was 100/60 mmHg, respiratory rate was 18 breaths per min, heart rate was 103 beats per min, and body temperature was 36.2°C. The patient's height and weight were 155.4 cm and 60.5 kg, respectively, her body mass index (BMI) was 25.05 kg/m 2 , and she had not experienced any recent changes in weight. Arterial blood gas analysis (ABGA) showed a metabolic acidosis with an increased anion gap of 19.5 mEq/L. Her plasma glucose levels were elevated to 431 mg/dL, and her serum osmolality, urea, and creatinine were also slightly elevated. Urine testing was positive for glucose (3+) and ketones (3+) ( Table 1 ). Based on these findings, the patient was Fulminant type 1 diabetes is observed particularly in East Asia, with several case reports and studies having originated from Japan. , and there is no difference in prevalence with respect to gender. 2, 3 Fulminant type 1 diabetes is also a well-known cause of pregnancy-related DKA. 6 In such cases, the onset is usually in the third trimester or immediately after delivery, and the prognosis for the fetus is extremely poor. 3, 7, 8 The exact pathogenesis of fulminant type 1 diabetes is unknown.
It has been suggested that certain genetic backgrounds pose an increased risk, including specific human leukocyte antigen (HLA)
types. According to studies performed in Japan, fulminant type 1 diabetes occurs to a greater extent in HLA-DR4, whereas HLA-DR9 is more common in typical type 1 diabetes. In addition, haplotype analysis has revealed that DR4-DQ4 is significantly more frequent in fulminant type 1 diabetes. 9,10 Viral infection is also suspected to play a role in the pathogenesis of this disease, with most patients exhibiting common cold-like and gastrointestinal symptoms prior to onset of disease. 11, 12 According to biopsies of the pancreas, severe reduction in the number of both β-and α-cells as well as lymphocytic infiltration of exocrine pancreatic tissue is often present. 5, 13 However, in our case, there was no evidence of infection based on the patient's history and physical examination. 16 Therefore, when DKA occurs in patients with type 2 diabetes, physicians should check for the presence of comorbid diseases.
In the patient in our case, DKA occurred without interruption in medication or presence of comorbid disease. The patient also denied use of any medications or herbal supplements capable of altering blood glucose levels. Finally, the patient's history and laboratory tests were sufficient to diagnose fulminant type 1 diabetes according to the diagnostic criteria proposed by Imagawa et al. 2 Therefore, fulminant type 1 diabetes mellitus should be included in the differential diagnosis of DKA occurring in a patient previously diagnosed with type 2 diabetes mellitus.
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